Renal cell carcinoma with central nervous system demyelination caused by nivolumab

IJU Case Reports

article

Toshiki Oka¹  Yoshiyuki Yamamoto¹  Yohei Okuda¹  Toshihisa Asakura¹  Koji Hatano¹  Yasutomo Nakai¹  Masashi Nakayama¹  Ken-ichi Kakimoto¹  Fuminobu Sugai²  Kazuo Nishimura¹ 

[1] Department of Urology, Osaka International Cancer Institute;Department of Neurology, Otemae Hospital

关键词: demyelination;    immune checkpoint inhibitor;    immune-related adverse event;    nivolumab;    renal cell carcinoma;   

DOI  :  10.1002/iju5.12234

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. Case presentation A 65-year-old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain-enhanced magnetic resonance imaging revealed multiple lesions with partial contrast effects in the cerebral white matter. We tentatively diagnosed demyelination caused by nivolumab, and performed steroid pulse therapy twice. After that, his symptoms improved. For the next 2 years, his symptoms did not recur, nor did his cancer progress. Conclusion Demyelination caused by immune checkpoint inhibitors can be fatal and requires early diagnosis and treatment.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND